MHRA Updates GLP-1 Guidance on Pancreatitis Risk

The Medicines and Healthcare products Regulatory Agency (MHRA) has updated its guidance for healthcare professionals and patients concerning Glucagon-Like Peptide-1 receptor agonists (GLP-1s). The update emphasizes the small but serious risk of severe acute pancreatitis associated with these drugs, which are prescribed for type 2 diabetes and weight management. Clinicians and patients are advised to remain vigilant for symptoms such as severe, persistent stomach pain that may radiate to the back, potentially accompanied by nausea and vomiting.

This guidance serves as a reminder of potential risks and encourages prompt medical attention if symptoms arise. The MHRA is also collaborating on research through the Yellow Card Biobank to investigate genetic predispositions to pancreatitis among GLP-1 users, aiming to improve personalized risk assessment and prescribing. Healthcare providers should ensure they are aware of the updated information and communicate it to relevant patients. Patients experiencing concerning symptoms should seek immediate medical advice and consider reporting via the Yellow Card scheme.